Buy Conmed

Logo for stock CNMD (Conmed)

Amount

£
GBP

Latest price

$65.00
(£1.00 = $1.242)

Number of shares (est.)

0

Start investing today

Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.

QR code linking to downloads for the Emma app.
Download on the App Store buttonGet it on Google Play button

Metrics

Market Cap

$2.08B

P/E ratio

15.84

EPS

$4.251

Beta

1.52

Dividend rate

$0.60

Dividend yield

0.89%

About

CONMED Corporation is a medical technology company, which provides surgical devices and equipment for minimally invasive procedures. Its products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Its product lines consist of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine and lower extremities instrumentation and implants, small bone, large bone, and specialty powered surgical instruments as well as imaging systems for use in minimally invasive surgery procedures and fees related to the sales representation, promotion, and marketing of sports medicine allograft tissue. General surgery consists of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments.

CEO

Mr. Patrick J. (Pat) Beyer

Employees

N/A

Sector

Health

Company HQ

LARGO, United States of America

Website

News

Logo for news article #0 (New Strong Sell Stocks for February 11th)

New Strong Sell Stocks for February 11th

ATS, CNMD and CSX have been added to the Zacks Rank #5 (Strong Sell) List on February 11, 2025.

Zacks Investment Research

February 11, 2025

Logo for news article #1 (CNMD's Q4 Earnings & Sales Beat Estimates, Stock Down on Weak Outlook)

CNMD's Q4 Earnings & Sales Beat Estimates, Stock Down on Weak Outlook

CONMED reports solid fourth-quarter results, fueled by strength in the General Surgery segment and continued demand for AirSeal product.

Zacks Investment Research

February 06, 2025

Logo for news article #2 (These Analysts Slash Their Forecasts On Conmed After Q4 Results)

These Analysts Slash Their Forecasts On Conmed After Q4 Results

CONMED Corporation CNMD posted better-than-expected earnings for its fourth quarter, but issued FY25 earnings and revenue guidance below estimates.

Benzinga

February 06, 2025

Emma logo
Facebook logoTiktok logoTwitter / X logoInstagram logo

© 2025 Emma Technologies Ltd. All Rights Reserved.

Emma is registered and incorporated in England and Wales.

Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).

Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.

Emma Technologies Ltd is an Introducer Appointed Representative of Quint Group Limited, which is authorised and regulated by the Financial Conduct Authority (FRN 669450). Emma Technologies Ltd is not a lender. Emma Technologies Ltd introduces customers to Monevo Limited who is a licensed credit broker.

Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.

Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.

All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.